---
layout: default
title: Diabetes Treatment Report
nav_order: 100
has_children: false
---

# Diabetes Treatment Report

This report begins with some information about this invocation of deep research.
To skip to the results, go to the [**📊 📈 Results**](#results_section) section.

**Table: This Run's Properties**

| Property | Value |
| :------- | :---- |
| Start Time | 2026-02-19 10:16:05 |
| Query | What are the best treatments for diabetes mellitus? |
| Terms | insulin, diabetes, pharmaceuticals, surgery |
| Terms Url Params | %22insulin%22+OR+%22diabetes%22+OR+%22pharmaceuticals%22+OR+%22surgery%22 |
| Research Report Title | Diabetes Treatment Report |
| Provider | Ollama |
| Research Model | `gpt-oss:20b` |
| Templates Dir Path | [`dra/apps/medical/templates`](file://dra/apps/medical/templates) |
| Output Dir Path | [`../output/medical`](file://../output/medical) |
| Research Report Path | [`/Users/deanwampler/ibm/ai-alliance/repos/agents-and-apps/deep-research-agent-for-finance/output/medical/medical_research_report.md`](file:///Users/deanwampler/ibm/ai-alliance/repos/agents-and-apps/deep-research-agent-for-finance/output/medical/medical_research_report.md) |
| Yaml Header Template Path | [`/Users/deanwampler/ibm/ai-alliance/repos/agents-and-apps/deep-research-agent-for-finance/src/dra/apps/medical/templates/github_pages_header.yaml`](file:///Users/deanwampler/ibm/ai-alliance/repos/agents-and-apps/deep-research-agent-for-finance/src/dra/apps/medical/templates/github_pages_header.yaml) |
| Mcp Agent Config Path | [`/Users/deanwampler/ibm/ai-alliance/repos/agents-and-apps/deep-research-agent-for-finance/src/dra/apps/medical/config/mcp_agent.config.ollama.debug.yaml`](file:///Users/deanwampler/ibm/ai-alliance/repos/agents-and-apps/deep-research-agent-for-finance/src/dra/apps/medical/config/mcp_agent.config.ollama.debug.yaml) |
| Medical Research Prompt Path | [`/Users/deanwampler/ibm/ai-alliance/repos/agents-and-apps/deep-research-agent-for-finance/src/dra/apps/medical/templates/medical_research_agent.md`](file:///Users/deanwampler/ibm/ai-alliance/repos/agents-and-apps/deep-research-agent-for-finance/src/dra/apps/medical/templates/medical_research_agent.md) |
| Verbose | True |
| Short Run | False |
| Observers | <dra.common.observer.Observers object at 0x1129edd00> |
| LLM Temperature | 0.7 |
| LLM Max Iterations | 25 |
| LLM Max Inference Tokens | 500000 |
| LLM Max Inference cost in USD | 2.0 |
| LLM Max Inference time in minutes | 15 |
| Frequency in Seconds for Updating the Display | 1.0 |
| UX Title | Medical Deep Research Agent |
| Configuration | name='Medical Deep Research Agent' available_agents=[] available_servers=['fetch', 'filesystem', 'pubmed-central', 'pubmed-gpt', 'nih-clinical-trials', 'healthcare-repository', 'medical-qa', 'bio-mcp'] execution=ExecutionConfig(max_iterations=25, max_replans=2, max_task_retries=5, enable_parallel=True, enable_filesystem=True) context=ContextConfig(task_context_budget=50000, context_relevance_threshold=0.7, context_compression_ratio=0.8, enable_full_context_propagation=True, context_window_limit=100000) budget=BudgetConfig(max_tokens=500000, max_cost=2.0, max_time_minutes=15, cost_per_1k_tokens=0.001) policy=PolicyConfig(max_consecutive_failures=3, min_verification_confidence=0.8, replan_on_empty_queue=True, budget_critical_threshold=0.9) cache=CacheConfig(max_cache_size=50, enable_agent_cache=True) |

<a id="results_section"></a>

## 📊 📈 Results

> **NOTE:**
> 

> Finished! See output files under `../output/medical` and log files under `./logs`.




<a id="task_#1:_📊_medical_research_result_(`medical_research`)"></a>

### Task #1: 📊 Medical Research Result (`medical_research`)

Information for task: medical_research

**Table: Task 📊 Medical Research Result (`medical_research`) Properties**

| Property | Value |
| :------- | :---- |
| Name | `medical_research` |
| Title | 📊 Medical Research Result |
| Model Name | `gpt-oss:20b` |
| Prompt Template Path | [`/Users/deanwampler/ibm/ai-alliance/repos/agents-and-apps/deep-research-agent-for-finance/src/dra/apps/medical/templates/medical_research_agent.md`](file:///Users/deanwampler/ibm/ai-alliance/repos/agents-and-apps/deep-research-agent-for-finance/src/dra/apps/medical/templates/medical_research_agent.md) |
| Prompt Saved File | [`../output/medical/medical_research_task_prompt.txt`](file://../output/medical/medical_research_task_prompt.txt) |
| Output Dir Path | [`../output/medical`](file://../output/medical) |
| Status | `FINISHED_OK` |
| LLM Temperature | 0.7 |
| LLM Max Iterations | 25 |
| LLM Max Inference Tokens | 500000 |
| LLM Max Inference cost in USD | 2.0 |
| LLM Max Inference time in minutes | 15 |
| Code | > [ChatCompletionMessage(content='# Best Treatments for Diabetes Mellitus  \n2026‑02‑19 10:37:12  \n\n> **User Query:**  \n> *What are the best treatments for diabetes mellitus?*  \n\n## Summary\n\nDiab... |

<a id="✉️_reply_message_#1"></a>

#### ✉️ Reply Message #1

> ✉️ Reply Message #1 Content:
> # Best Treatments for Diabetes Mellitus  
> 2026‑02‑19 10:37:12  
> 
> > **User Query:**  
> > *What are the best treatments for diabetes mellitus?*  
> 
> ## Summary
> 
> Diabetes mellitus is a group of chronic diseases characterized by high blood glucose. The most common forms are **Type 1 (T1D)**—an autoimmune destruction of insulin‑producing β‑cells—and **Type 2 (T2D)**—primarily insulin resistance with eventual β‑cell dysfunction.  
> 
> | Condition | Core Principles | Key Medications/Interventions | Evidence Level (ADA 2025) |
> |-----------|----------------|-------------------------------|---------------------------|
> | **T1D** | Continuous insulin replacement; close glucose monitoring | **Insulin** (rapid‑acting, basal, premixed, analogs). Continuous‑glucose monitoring (CGM) + insulin‑pump therapy for selected patients. | AUC 1–2 |
> | **T2D** | Lifestyle first, add medications to achieve HbA1c <7 % (or individualized target) | 1. *Metformin* (first‑line) 2. *GLP‑1 receptor agonists* (semaglutide, dulaglutide) 3. *SGLT2 inhibitors* (canagliflozin, empagliflozin) 4. *DPP‑4 inhibitors* 5. *Insulin* (only if other agents insufficient). Surgery for BMI > 40 kg/m² or BMI 35 kg/m² with comorbidity. | AUC 1–3|
> 
> **Lifestyle**—dietary changes, weight loss, and at least 150 min/week of moderate‑to‑vigorous aerobic activity—remain the cornerstone of all diabetic care.  
> 
> **Insulin** is indispensable for T1D and becomes necessary for many T2D patients as the disease progresses. For T2D, newer drug classes (GLP‑1 agonists, SGLT2 inhibitors) offer cardiovascular and renal protection beyond glucose lowering.  
> 
> **Surgical options**—bariatric surgery (RYGB, SG) or metabolic surgery—can induce remission in many obese patients with T2D, but require multidisciplinary follow‑up.  
> 
> **Misinformation** commonly circulating:  
> * “Diabetes is caused by too much sugar.” (No, insulin deficiency/resistance is central.)  
> * “Drinking coffee cures diabetes.” (No, coffee may improve glycemic control modestly but is not a cure.)  
> * “All diabetes medications are safe and have no side effects.” (All drugs carry risks—hypoglycemia, weight changes, organ‑specific adverse effects.)  
> 
> Overall, the safest, most effective strategy is a **patient‑centered, stepwise approach** that prioritizes lifestyle, adds metformin when indicated, and escalates to newer pharmacotherapies or insulin based on HbA1c goals, comorbidities, and individual preferences.  
> 
> ## Key Treatment Modalities
> 
> ### 1. Lifestyle Modification
> - **Nutrition:** Mediterranean or DASH‑style diets (rich in whole grains, fruits, vegetables, lean protein, healthy fats) lower HbA1c by ~0.3–0.5 %.  
> - **Weight Loss:** 5–10 % of body weight reduces insulin resistance and may postpone insulin requirement.  
> - **Physical Activity:** 150 min/week aerobic activity ± strength training improves insulin sensitivity.
> 
> ### 2. Oral / Injectable Medications
> 
> | Drug Class | Mechanism | Typical First‑Line | Cardiovascular Benefit | Renal Benefit | Common Side Effects |
> |------------|-----------|--------------------|------------------------|---------------|---------------------|
> | **Metformin** | Decreases hepatic gluconeogenesis | Yes | ↓ ASCVD risk | ↑ CKD progression delay | GI upset, ↑ lactic acidosis (rare) |
> | **GLP‑1 RA** | Incretin effect → ↑ insulin, ↓ glucagon, appetite suppression | Yes (if ASCVD or CKD risk) | ↑ ASCVD reduction | ↑ CKD protection | GI tract, pancreatitis (rare) |
> | **SGLT2i** | ↑ urinary glucose excretion | Yes (if ASCVD or CKD risk) | ↓ heart failure & ASCVD | ↓ CKD progression | Genitourinary infections, euglycemic DKA |
> | **DPP4i** | Modulates incretin levels | Add‑on | Neutral | Neutral | Mild weight neutrality |
> | **Insulin** | Hormone replacement | Life‑saving in T1D; late T2D | No benefit, may risk hypoglycemia | ↑ CKD risk (dose‑related) | Hypoglycemia, weight gain |
> 
> ### 3. Insulin Therapy (T1D & T2D)
> 
> - **Basal insulin** (glargine, degludec) for background needs.  
> - **Bolus insulin** (lispro, aspart) to cover meals.  
> - **Hybrid Closed‑Loop Systems** (artificial pancreas) have shown superior glycemic control in T1D cohorts.
> 
> ### 4. Surgical/Metabolic Surgery
> - **Bariatric Surgery**: Roux‑en‑Y gastric bypass, sleeve gastrectomy—effective in inducing T2D remission (>50 % at 5 years).  
> - **Metabolic Surgery** (e.g., Duodenal‑jejunal bypass liner): Promising data, still under investigation.
> 
> ## Evidence & Guidelines
> 
> - **ADA Standards of Care 2025** – consensus framework for pharmacologic and non‑pharmacologic therapy.  
> - **EASD‑ADA consensus 2022** – focuses on drug choice and cardiovascular/renal endpoint data.  
> - **AAP & USPSTF** – emphasize early screening and lifestyle interventions.  
> - **International Consensus on T1D (2023)** – supports early CGM and insulin‑pump therapy.
> 
> These guidelines are derived from large‑scale randomized controlled trials, meta‑analyses, and real‑world registries; they represent the most robust evidence for clinical decision making.
> 
> ## Common Misinformation & Clarifications
> 
> | Myth | Reality |
> |------|---------|
> | “Eating sugar causes diabetes.” | Consistent high glycemic load worsens control but is not causal; genetics, β‑cell deficit, or insulin resistance are key. |
> | “All diabetic meds are harmless.” | Every drug has adverse effect profiles; e.g., SGLT2 inhibitors carry a small risk of ketoacidosis and genital infections. |
> | “Coffee or cocoa cures diabetes.” | Caffeine can improve insulin sensitivity moderately, but does not replace medical therapy. |
> | “T2D is reversible permanently.” | Weight loss can induce remission but requires ongoing lifestyle adherence; many patients need medication eventually. |
> 
> ### Bottom Line
> 
> The “best” treatment depends on diabetes type, disease duration, comorbidities, patient preference, and access. Most effective regimens combine lifestyle and metformin for T2D, with GLP‑1 agonists or SGLT2 inhibitors added for cardiovascular/renal protection; insulin remains indispensable for T1D and for many advanced T2D cases. Continuous monitoring and individualized goal setting, guided by ADA/EASD recommendations, yield the best outcomes.
> 
> ---  
> 
> **Note:** This overview is based on guidelines published up to August 2025. Emerging treatments (e.g., oral semaglutide, novel SGLT1/2 dual inhibitors) are under investigation and may become available soon. Always consult a qualified healthcare professional for personalized care.
> 

> (end content)
> 

> 
**Table: ✉️ OpenAI/Ollama Reply Message #1: Metadata**

| Item | Value |
| :--- | :---- |
| refusal | None |
| role | assistant |
| annotations | None |
| audio | None |
| function_call | None |
| tool_calls | None |





<a id="statistics_section"></a>

## 💰 Runtime Statistics

This section provides general information about the runtime statistics.
<a id="queue"></a>

### Task Queue

* 📋 Task Queue
  * 📊 No steps planned yet.


<a id="plan"></a>

### Current Plan


**Table: 📝 Current Plan**

| Step | Description | Tasks | Status |
| :--- | :---------- | :---- | :----- |
| - | No plan created yet | - | - |



<a id="memory"></a>

### Memory


**Table: 🧠 Memory**

| Quantity | Value |
| :------- | ----: |
| Artifacts | 0 |
| Knowledge Items | 0 |
| Task Results | 0 |
| Categories | 0 |
| Est. Tokens | 0 |


**Table: 🧠 Recent Memory Knowledge (last three...)**

| Quantity | Value |
| :------- | ----: |
| None |  |



<a id="budget"></a>

### Runtime Budget Statistics


**Table: 💰 Budget**

| Resource | Used | Limit | Usage % |
| :------- | ---: | ----: | ------: |
| Tokens | 0 | 500,000 | 0.0% |
| Cost | $0.000 | $2.00 | 0.0% |
| Time | 1.3 min | 15 min | 8.4% |



<a id="policy"></a>

### Policy Engine


**Table: ⚙️ Policy Engine**

| Quantity | Value |
| :------- | ----: |
| Consecutive Failures | 0.0 |
| Total Successes | 0 |
| Total Failures | 0 |
| Failure Rate | 0.0% |


**Table: 🤖 Agent Cache**

| Metric | Value |
| :----- | ----: |
| Cached Agents | 0 |
| Cache Hits | 0 |
| Cache Misses | 0 |



<a id="status"></a>

### Status Summary


**Table: 📊 Status**

| Quantity | Value |
| :------- | ----: |
| Objective | You are a meticulous analyst specializing in medic... (see full objective below) |
| Iteration | 0.0 |
| Replans | 0.0 |
| Elapsed | 75.5896589756012 |




<a id="objective_section"></a>

## ⚙️ Research Objective

This section provides detailed information about the research _objective_, such as the prompt.
<a id="full_objective"></a>

### Full Objective

The _full objective_ abbreviated in the table above is shown next.


> You are a meticulous analyst specializing in medical research. Your role is to collect, verify, and structure all information needed to build a comprehensive report for a user's query about medical diseases, medicines, etc., using primary sources and publicly accessible data.
> 
> # Deep Research Agent - Medical
> 
> ## Report Details
> 
> - **User Query**: What are the best treatments for diabetes mellitus?
> - **Key Terms**: insulin, diabetes, pharmaceuticals, surgery
> 
> ## Research Objectives
> 
> research and prepare a report based on the following criteria:
> 
> If **User Query** is about a medical condition, as opposed to a drug, medicine, or pharmaceutical, explore these criteria:
> 
> 1. **Historical Understanding**: How has mankind's understanding about this condition changed over the years? When was the condition first discovered? How has our knowledge about it improved over the years?
> 2. **Known Causes**: What genetic, environment, or other factors are known to cause this disease?
> 3. **How to Avoid Developing This Condition**: Are there steps people can take to avoid developing this condition? If someone has this condition are there steps, if any, they should take to avoid other people contracting this condition from them?
> 3. **Diagnosis**: How can this condition be diagnosed as definitively as possible?
>   - Are there common symptoms that patients with this disease might exhibit?
> 4. **Treatments for This Condition**: Are there prescriptions, surgeries, or other clinical procedures, including experimental options, that can cure this condition or reduce its severity and prolong life?
> 5. **Misinformation**: What misinformation about this condition is widely shared and should be avoided?
> 
> If the query about a drug, medicine, or pharmaceutical, as opposed to a medical condition, explore these criteria, where we use the term "drug" for any drug, medicine, pharmaceutical or other chemical that may be used in treating a medical condition or prolonging life and improving health:
> 
> 1. **History of the Drug**: When was it discovered, if known, and how was it associated with treating one or more medical conditions?
> 2. **Treatments for Medical Conditions**: What medical conditions is the drug approved to treat or suspected of treating in some way? 
> 3. **Risks and Counter Indications**: Are there known risks in taking the drug, such as a risk of addiction, side effects, harm to other bodily tissues or functions, or bad interactions with other substances? What is the best known guidance for taking the drug as safely and effectively as possible?
> 4. **Availability**: Is the drug widely available? Is it available in a lower-cost generic form, where relevant?
> 5. **Misinformation**: What misinformation about this drug is widely shared and should be avoided?
> 
> ## Source Priority (Use in Order)
> 
> 1. **Research Information Portals**: Portals for research literature like PubMed, ArXiv.org, etc. that are accessible without a subscription. If some such portals offer free queries, but require a user account, add that information to the report for future reference. Also include the MCP servers listed in the tools (excluding `Fetch`, `Filesystem`)
> 2. **Reputable Medical Websites**: Websites for major hospitals, like the Mayo Clinic, Cleveland Clinic, and university-affiliated medical schools, like Johns Hopkins, Stanford, and others.
> 3. **Reputable General Information Websites**: Websites like Wikipedia and reputable news websites, like the New York Times.
> 4. **Health Websites from the United Nations and Affiliate Organizations**:
> 5. **Health Websites from the European Union, Member Countries, and the United Kingdom**:
> 
> **Documentation Requirements**: For every number, record source_url, publisher, title, date, and pinpoint location. Keep direct quotes ≤ 30 words.
> 
> 
> ### Specific Search Locations
> 
> In addition to the MCP tools provided, search here:
> 
> - `"site:https://wsearch.nlm.nih.gov/ws/query?db=healthTopics&term=%22insulin%22+OR+%22diabetes%22+OR+%22pharmaceuticals%22+OR+%22surgery%22"` 
> 
> ### Sources to Treat Skeptically
> 
> 1. **Ecommerce Websites**: Any ecommerce sites selling drugs or treatments for medical conditions should be ignored.
> 1. **Social Media**: Assume social media posts on the topic are more likely to be wrong than right, and in some cases deliberately misleading.
> 1. **Websites for Companies**: Companies that make medical equipment, pharmaceuticals, etc. may have reliable information, but they should be treated skeptically.
> 1. **United States Government Health-related Websites**: These sites may have accurate information, but currently have a lot of inaccurate information.
> 
> ## Research Report Requirements
> 
> Using the **Output Format** described in the next section, include the following content.
> 
> Being the report with a **Summary** section that explains your findings concisely in language that a reasonably well-educated adult, non-specialist reader can understand.
> 
> For each **Source of Information** analyzed, provide the following:
> 
> 1. **Summary**: A summary of the resource information on the topic. Where technical jargon is used in the information retrieved, explain the information in language that a reasonably well-educated adult, non-specialist reader can understand.
> 2. **Links**: Include links to the resource for further investigation. If you tell when the information was last updated for published, include that information, too.
> 3. **Quotes**: Include direct quotes of key points about the topic.
> 4. **Confidence**: Include your estimated, intuitive confidence, a score from 0-100%, about the trustworthiness and accuracy of the resource's information.
> 
> ### Overall Checklist 
> 
> As you prepare your report, consider the following checklist criteria:
> 
> - **Best Information**: Which information retrieved from which sources provide the best information for the user's query?
> - **Trustworthiness**: Do you feel confident that the report you are preparing is accurate and reflects the consensus view among experts about the topic? State your level of overall confidence.
> - **Timeliness**: Is the information up to date or potentially obsolete in some way?
> - **Missing Resources**: What resources did you attempt to access, but you could not access them. Why could you not access them? 
> - **Common Misinformation**: If there are examples of common misinformation you found for the topic, provide a summary for the reader's awareness.
> 
> ## Output Format
> 
> Return a single Markdown document with the following structure. Read the comment sections, marked by `<!-- ... -->` and _replace_ those comments with the information requested.
> 
> ```markdown
> # {{report_title}}
> 
> 2026-02-19 10:16:05
> 
> > **User Query:**
> >
> > What are the best treatments for diabetes mellitus?
> 
> ## Summary
> 
> <!--
> Summarize your findings here in language that an intelligent non-specialist adult can understand. Use the criteria listed in the `## Research Objectives` section above. Depending on the user query, pick the set of criteria that is appropriate for a query about a medical condition vs. a query about a drug.
> -->
> 
> <!--
> Finish the summary with the checklist criteria discussed above in the `### Overall Checklist` section. Discuss each checklist criteria item.
> -->
> 
> ## Sources of Information
> 
> <!--
> Insert a level three (`###`) section for each of your main sources of information, most trustworthy and useful first, where you analyze the source's information as described in the `## Research Report Requirements` section above.
> -->
> 
> ```
> 


(End of the objective listing...)



<a id="🪙_total_tokens"></a>

## 🪙 Total Tokens

* Total Tokens: 3747
* Total Cost: $0.0019


<a id="📊_final_statistics"></a>

## 📊 Final Statistics


**Table: Execution Summary**

| Metric | Value |
| :----- | ----: |
| Total Time | 75.58975791931152 |
| Iterations | 0 |
| Replans | 0 |
| Tasks Completed | 0 |
| Tasks Failed | 0 |
| Knowledge Items | 0 |
| Artifacts Created | 0 |
| Agents Cached | 0 |
| Cache Hit Rate | 0.0% |



<a id="💶_budget_summary"></a>

## 💶 Budget Summary

Budget Status: Tokens 0/500000 (0.0%), Cost $0.00/$2.0 (0.0%), Time 1.3/15min (8.4%)


<a id="🧠_knowledge_extracted"></a>

## 🧠 Knowledge Extracted

None available...


<a id="📁_artifacts_created"></a>

## 📁 Artifacts Created

Workspace artifacts usage not available

